Primary renal aspergillosis and renal stones in both kidneys associated with hematopoietic stem cell transplant

Hyunsung Park¹, Mi Jung Lee¹, Yundeok Kim¹, Yoo Hong Min¹, Soo Jeong Kim¹, Dokyung Kim²

¹Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, ²Department of Pathology, Yonsei University College of Medicine, Seoul, Korea

INTRODUCTION

Invasive aspergillosis (IA) is a major cause of morbidity and mortality in patients who have undergone a hematopoietic stem cell transplant (HSCT). The common sites of IA include lung, central nervous system, and paranasal sinuses. Primary renal aspergillosis is extremely rare; it has been mostly reported in immunocompromised patients. In Korea, only 3 cases of primary renal aspergillosis have been reported [1-3], but none were associated with HSCT. We report a patient who developed primary renal aspergillosis and renal stones in both the kidneys after HSCT. Invasive renal aspergillosis was diagnosed after a nephrectomy, which was performed to treat massive renal hematoma.

CASE REPORT

A 33-year-old man was hospitalized after experiencing general weakness for 1 month. His medical history was unremarkable. Bone marrow examination revealed acute myeloid leukemia (AML). He received induction chemotherapy comprising continuous infusion of cytarabine (100 mg/m²) for 7 days and bolus injection of idarubicin (12 mg/m²) for 3 days. He achieved complete remission, and the same drugs were administered during consolidation chemotherapy. At the end of the first consolidation chemotherapy, he visited the outpatient clinic because of severe headache. Cerebrospinal fluid (CSF) cytology confirmed leukemia relapse in the central nervous system (CNS). Bone marrow examination did not show any evidence of hematologic relapse. Isolated CNS relapse was treated by intrathecal injection of methotrexate (12 mg; twice weekly). After the 4th injection, leukemic blasts in the CSF were unidentifiable. Therefore, methotrexate injection was discontinued after 2 additional courses. The patient received allogeneic peripheral blood SCT from a HLA-2-mismatched unrelated donor. Abdominal ultrasonography before the transplant had revealed renal stones with hydronephrosis in the right kidney. Since the patient had no specific symptoms related to renal stones, HSCT was continued without further treatment for renal stones. The conditioning regimen comprised busulphan (3.2 mg/kg; IV; 4 days) and cyclophosphamide (60 mg/kg; IV; 2 days). Tacrolimus and short-course methotrexate were administered for the prophylaxis of graft-versus-host disease
Fig. 1. Multiple renal and ureteral stones (arrow) with hydroureter.

Fig. 2. Images of the renal parenchymal tearing with active bleeding, subcapsular hematoma in the right kidney (left panel), and prostate abscess (right panel).
(Fig. 3), and a ruptured area in the mid-portion of the lateral side of the right kidney was observed. Moreover, multiple fungal hyphae with septae and branching at acute angles in the renal parenchyma with vascular invasion, which was morphologically consistent with renal aspergillosis, were observed (Fig. 4). The identity of the causative fungal pathogen was inconclusive. The abscess-like lesion in the prostate was not manipulated because of the risk for hemorrhage. The patient was initially treated with meropenem and vancomycin for broad-spectrum antibacterial coverage and amphotericin B deoxycholate for empirical antifungal coverage after the development of fever. After confirmation of renal aspergillosis, voriconazole was administered instead of amphotericin B deoxycholate at the intensive care-unit after the operation, but the patient died on day 113 because of sepsis progression.

**DISCUSSION**

Aspergillus is a filamentous fungus occurring naturally worldwide. Aspergillus spp., Fusarium spp., and Pseudallescheria boydii show branched septate hyphae with angioinvasion, but Fusarium spp. show branching at right angles and constriction at their site of origin from parent hyphae and Pseudallescheria boydii show haphazard branching with prominent vesicles [4]. More than 900 species of *Aspergillus* exist, but less than 20 are pathogenic to humans [3]. *Aspergillus fumigatus* is the most common causative pathogen in invasive aspergillosis, followed by *A. flavus*, *A. niger*, and *A. terreus* [3].

IA is a leading cause of infectious mortality after HSCT. Although supportive care has improved and new antifungal agents and sensitive tests such as *Aspergillus* galactomannan antigen assay have been developed, mortality due to IA is high (70-93%) in HSCT patients [5]. The incidence of IA among the HSCT recipients has increased since the 1990s; this may be attributed to the grafts obtained from high-risk donors, increased profound immunosuppression, and prophylaxis with fluconazole, which is active against most *Candida* species but not against *Aspergillus* species. In recent years, IA has been the most common invasive fungal infection (IFI) following HSCT, accounting for 59% of IFIs [6].

In 2008, the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) classified IFI into proven, probable, or possible disease [7]. The *Aspergillus* galactomannan antigen test forms a part of the reference standard for diagnosing IA under the EORTC/MSG criteria.
The sensitivity and specificity of this test were 71% and 89%, respectively, for proven cases, and 61% and 93% for proven and probable cases, respectively, in patients with neutropenia or other hematologic conditions [8], although false positive results may be obtained from patients receiving piperacillin, amoxicillin, or ticarcillin [9].

In our patient, the positive finding of serum galactomannan was first reported on day 75, and the subsequent tests were positive, with a continuously high titer. According to the EORTC/MSG classification, we diagnosed the patient with possible fungal infection and treated him with amphotericin B deoxycholate. Unfortunately, after 2 weeks of treatment, the serum galactomannan levels did not decrease, which may be attributed to the following reasons. First, although amphotericin B is used as a standard therapy for IA, only 13.3% of patients who had undergone allogenic HSCT had shown a favorable response [10]. Second, since amphotericin B is excreted mainly via the biliary tract (42%) and only a low percentage is excreted via the kidney (24%) [3], there is a possibility that the amphotericin B deoxycholate concentration is not sufficient to eliminate Aspergillus from the kidney. Finally, although Aspergillus species are rarely resistant to amphotericin B, the patient may have been infected by A. terreus, which is intrinsically resistant to amphotericin B. Itraconazole, which was administered subsequently after amphotericin B deoxycholate, is active against most Aspergillus species, including A. terreus. However, since itraconazole is mostly excreted in the feces, it may not be effective against renal aspergillosis. Therefore, surgical treatment of renal aspergillosis may achieve a good outcome [3]. If surgery cannot be performed, voriconazole and/or caspofungin can be administered, though the data on their efficacies are still limited [10, 11]. In our case, the patient had undergone radical nephrectomy, during which renal aspergillosis was incidentally observed. Extensive imaging studies were performed before surgery, but contrast non-enhanced CT scan and ultrasonography were not sufficient to identify the fungal lesions in the kidney. If IA is highly suspected in patients with kidney complications, aggressive diagnostic approaches, including contrast-enhanced imaging study (e.g., CT and MRI) may facilitate an accurate diagnosis and improve the treatment outcome.

In the only report of primary renal aspergillosis following HSCT, the patient had a stone in the renal pelvis [12]; this clinical presentation was similar to that observed in our patient. Many other reports have described the simultaneous presentation of renal aspergillosis and urinary tract stones. Haq et al. [13] reported primary renal aspergillosis in a diabetic patient with renal stones and Godec et al. and Eisenberg et al. reported cases with primary renal aspergillosis and obstruction at the ureteropelvic junction [14, 15]. These findings may suggest that urinary stasis induced by urinary tract obstruction may play some role in the development of renal aspergillosis.

In conclusion, the development of primary renal aspergillosis following HSCT is extremely rare, but if fungal infection is suspected in a patient with a urinary tract obstruction, especially with renal stones, renal aspergillosis must be considered in the differential diagnosis.

REFERENCES

1. Kwon O, Woo JG, Yi JE, Jung GW, Cho S, Kim SR. A case of invasive aspergillosis limited to renal allograft. Korean J Nephrol 2010;29:300-4.
2. Na HH, Hong SW, Kim MC, Kang YK, Yoon YC, Koh HI. A case of invasive aspergillosis in transplanted kidney and perirenal area. J Korean Soc Transplant 2008;22:135-7.
3. Chung WB, Lee DG, Choi YK, et al. A case of isolated renal aspergillosis in a patient with acute myelocytic leukemia. Korean J Med 2004;67(Suppl 3):S845-9.
4. Watts JC, Chandler FW. Aspergillosis. In: Connor DH, Chandler FW, Schwartz DA, et al. eds. Pathology of infectious diseases. Vol. 2. Stamford, USA: Appleton & Lange, 1997:933-41.
5. Upton A, Kirby KA, Carpenter P, Boechk M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-40.
6. Chandrasekar PH, Ramesh M. Challenges in the management of invasive aspergillosis in hematopoietic stem cell transplantation. Expert Rev Anti Infect Ther 2009;7:1151-3.
7. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21.
8. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42:1417-27.
9. Wheat LJ. Approach to the diagnosis of invasive aspergillosis and candidiasis. Clin Chest Med 2009;30:367-77.
10. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
11. Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010;45:1227-33.
12. de Medeiros CR, Dantas da Cunha A Jr., Pasquini R, Arns da Cunha C. Primary renal aspergillosis: extremely uncommon presentation in patients treated with bone marrow transplantation. Bone Marrow Transplant 1999;24:113-4.
13. Haq JA, Khan MA, Afroz N, Haq T. Localized primary renal aspergillosis in a diabetic patient following lithotripsy—a case report. BMC Infect Dis 2007;7:58.
14. Godec CJ, Mielenick A, Hilfer J. Primary renal aspergillosis. Urology 1989;34:152-4.
15. Eisenberg RL, Hedgcock MW, Shanser JD. Aspergillus mycetoma of the renal pelvis associated with ureteropelvic junction obstruction. J Urol 1977;118:466-7.

Korean J Hematol 2010;45:275-8.